Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics, a clinical-stage company specializing in heart disease treatments, has completed a public offering, raising US$13.5 million through the sale of its Class A common shares. These funds are earmarked for the clinical development of CardiolRx, aimed at treating recurrent pericarditis, and other corporate expenses.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
